Realta Investment Advisors Has $193,000 Holdings in CVS Health Co. (NYSE:CVS)

Realta Investment Advisors reduced its stake in shares of CVS Health Co. (NYSE:CVS) by 6.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,209 shares of the pharmacy operator’s stock after selling 281 shares during the period. Realta Investment Advisors’ holdings in CVS Health were worth $193,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Beacon Financial Advisory LLC lifted its holdings in CVS Health by 4.4% in the 4th quarter. Beacon Financial Advisory LLC now owns 14,088 shares of the pharmacy operator’s stock worth $632,000 after purchasing an additional 600 shares during the last quarter. Tectonic Advisors LLC raised its position in shares of CVS Health by 12.6% in the fourth quarter. Tectonic Advisors LLC now owns 14,497 shares of the pharmacy operator’s stock valued at $651,000 after purchasing an additional 1,619 shares during the period. Lion Street Advisors LLC boosted its holdings in shares of CVS Health by 18.3% during the 4th quarter. Lion Street Advisors LLC now owns 8,369 shares of the pharmacy operator’s stock worth $376,000 after buying an additional 1,295 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in CVS Health by 25.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 132,645 shares of the pharmacy operator’s stock valued at $5,884,000 after buying an additional 26,589 shares during the last quarter. Finally, Y.D. More Investments Ltd acquired a new position in CVS Health during the 4th quarter worth $144,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Stock Performance

CVS Health stock opened at $53.95 on Friday. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $80.75. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.80 and a quick ratio of 0.59. The stock has a fifty day moving average price of $50.90 and a two-hundred day moving average price of $56.02. The firm has a market capitalization of $67.90 billion, a P/E ratio of 13.69, a P/E/G ratio of 0.62 and a beta of 0.61.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.01. The firm had revenue of $95.43 billion for the quarter, compared to analyst estimates of $92.72 billion. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The company’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.21 earnings per share. As a group, analysts anticipate that CVS Health Co. will post 5.14 EPS for the current fiscal year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Thursday, January 23rd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, January 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 4.93%. CVS Health’s dividend payout ratio (DPR) is presently 67.51%.

Wall Street Analyst Weigh In

CVS has been the topic of several research analyst reports. Barclays lowered their price target on CVS Health from $75.00 to $71.00 and set an “overweight” rating on the stock in a research report on Thursday, November 7th. Royal Bank of Canada dropped their price target on CVS Health from $68.00 to $58.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. Evercore ISI increased their price objective on CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a research report on Monday, January 27th. Wells Fargo & Company upgraded shares of CVS Health from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $60.00 to $66.00 in a research note on Monday, November 18th. Finally, Mizuho decreased their price target on shares of CVS Health from $73.00 to $66.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $68.12.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.